Teva Plots Out 2026 Launch For ‘Night And Day’ Olanzapine Long-Acting Injectable
Firm Excited About Potential To ‘Layer Olanzapine On Top’ Of Risperidone LAI
At the J.P. Morgan Healthcare Conference in San Francisco, Teva has provided a timeline for its much-talked-about long-acting injectable olanzapine candidate, after wrapping up a Phase III clinical trial with data that the firm believes will give it a major advantage over its competitors.
